Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the progression free survival (PFS) of metastatic
ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab
(Avastin®) therapy.